Inhibrx and bluebird bio began a research collaboration in 2016. Since that time, the collaboration has focused on researching, developing, and commercializing chimeric antigen receptor (CAR) T-cell therapies using Inhibrx’s proprietary single-domain antibody (sdAb) platform to multiple cancer targets.
- In 2018, Inhibrx granted bluebird worldwide rights to develop, manufacture, and commercialize certain cell therapy products.
- In 2020, Inhibrx granted bluebird exclusive worldwide rights to develop binders and cell therapy products containing sdAbs directed to specified targets for two programs and up to an additional eight programs.